Recruiting CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies NCT05442515 Conditions Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Lymphoid Leukemia, +34 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
Recruiting JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917 Conditions B-ALL, B-NHL Locations Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China — Wuhan, Hubei, China View Trial Details
Recruiting Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL NCT06695013 Conditions B-NHL, CART Therapy Locations Ruijin — Shanghai, Shanghai Municipality, China View Trial Details
Recruiting JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06678282 Conditions B-ALL, B-NHL Locations The First Affiliated Hospital of Zhengzhou University — Zhenzhou, Henan, China View Trial Details
Completed Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies NCT02315612 Conditions ALL, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, +32 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
Completed CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies NCT03448393 Conditions Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Lymphoid Leukemia, +33 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
